

PIPEX PHARMACEUTICALS, INC.

Form 8-K

May 02, 2008

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 1, 2008

Pipex Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

01-12584

13-3808303

(State or other jurisdiction of

(Commission

(IRS Employer

incorporation)

File Number)

Identification Number)

3930 Varsity Drive

Ann Arbor, MI 48108

**(Address of principal executive offices) (Zip Code)**

(734) 332-7800

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01 Other Events.**

On May 1, 2008, the Registrant was informed that the manuscript describing the results of an 80 patient, randomized, double-blind, placebo-controlled clinical trial of oral zinc-monocysteine (oral Z-monocys) for the treatment of dry age-related macular degeneration (AMD) has completed the peer review process and has been accepted for publication by a peer reviewed medical ophthalmology journal. The Registrant had previously disclosed that oral Z-monocys therapy had demonstrated statistically significant improvement in visual acuity and other key markers of retinal function.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 1, 2008

PIPEX PHARMACEUTICALS, INC.  
By: /s/ Steve H. Kanzer          +  
Steve H. Kanzer, Chairman & CEO